0000950123-08-002191 Sample Contracts
DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT By and Between AVENTIS PHARMACEUTICALS INC. and REGENERON PHARMACEUTICALS, INC. Dated as of November 28, 2007Discovery and Preclinical Development Agreement • February 27th, 2008 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS DISCOVERY AND PRECLINICAL DEVELOPMENT AGREEMENT (“Agreement”), dated as of November 28, 2007 (the “Effective Date”), is by and between AVENTIS PHARMACEUTICALS INC. (“Sanofi”), a corporation organized under the laws of Delaware, having a principal place of business at 55 Corporate Boulevard, Bridgewater, New Jersey 08807, an indirect wholly owned subsidiary of Sanofi-Aventis, a company organized under the laws of France with its principal headquarters at 174, avenue de France, 75103 Paris, France (“Sanofi Parent”), and REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, USA (“Regeneron”) (with each of Sanofi and Regeneron referred to herein individually as a “Party” and collectively as the “Parties”).
Standard Contracts
LICENSE AND COLLABORATION AGREEMENT By and Among AVENTIS PHARMACEUTICALS INC., SANOFI-AVENTIS AMERIQUE DU NORD and REGENERON PHARMACEUTICALS, INC. Dated as of November 28, 2007License and Collaboration Agreement • February 27th, 2008 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), dated as of November 28, 2007 (the “Effective Date”), is by and between AVENTIS PHARMACEUTICALS INC., a corporation organized under the laws of the state of Delaware having a principal place of business at 55 Corporate Drive, Bridgewater, New Jersey 08807 (“Sanofi”), an indirect wholly owned subsidiary of sanofi-aventis, a company organized under the laws of France with its principal headquarters at 174, avenue de France, 75013 Paris, France (“Sanofi Parent”), SANOFI-AVENTIS AMERIQUE DU NORD, a partnership organized under the laws of France with its principal headquarters at 174 avenue de France, 75013 Paris, France (“Sanofi Amerique”), and REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of the state of New York having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) (with each of Sanofi and Regeneron being sometimes referred to herein individually a
INVESTOR AGREEMENT By and Among SANOFI-AVENTIS, SANOFI-AVENTIS US LLC, AVENTIS PHARMACEUTICALS INC., SANOFI-AVENTIS AMÉRIQUE DU NORD AND REGENERON PHARMACEUTICALS, INC. Dated as of December 20, 2007Investor Agreement • February 27th, 2008 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of December 20, 2007, by and among sanofi-aventis, a company organized under the laws of France, with its principal headquarters at 174, avenue de France, 75013 Paris, France (“sanofi-aventis”), sanofi-aventis US LLC, a Delaware limited liability company indirectly wholly owned by sanofi-aventis (“Sanofi US”) and the successor-in-interest to Aventis Pharmaceuticals Inc. (“Aventis”) with respect to the Aventis Collaboration Agreement, with its headquarters at 55 Corporate Drive, Bridgewater, New Jersey 00807, Aventis, a Delaware corporation and an indirect wholly owned subsidiary of the Investor with its headquarters at 55 Corporate Drive, Bridgewater, New Jersey 00807, sanofi-aventis Amérique du Nord, a société en nom collectif organized under the laws of France wholly owned by sanofi-aventis with its principal headquarters at 174, avenue de France, 75013 Paris, France (the “Investor”, and, together with sanofi-aventis, Sanofi US an
STOCK PURCHASE AGREEMENT By and Among SANOFI-AVENTIS AMÉRIQUE DU NORD, SANOFI- AVENTIS US LLC AND REGENERON PHARMACEUTICALS, INC. Dated as of November 28, 2007Stock Purchase Agreement • February 27th, 2008 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of November 28, 2007, by and among sanofi-aventis Amérique du Nord (the “Investor”), a société en nom collectif organized under the laws of France and wholly owned by sanofi-aventis, a company organized under the laws of France (“sanofi-aventis”), with its principal headquarters at 174, avenue de France, 75013 Paris, France, sanofi-aventis US LLC (solely for purposes of Sections 5.11, 8.2, 8.3, 11.2 and 12.13), a Delaware limited liability company indirectly wholly owned by the Investor (“Sanofi US”) and the successor in interest to Aventis Pharmaceuticals Inc., a Delaware corporation indirectly wholly owned by the Investor (“Aventis”), with respect to the Aventis Collaboration Agreement, with its headquarters at 55 Corporate Drive, Bridgewater, New Jersey 00807, and Regeneron Pharmaceuticals, Inc. (the “Company”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10
